drugs of long half life [Design Issues]
Hi John!
Yessir.
Nope. The residual variance in a parallel design is also the total. What Niazi writes:
@Ken:
Don’t fall into the trap of basing you design on a reported mean value. Take the variability into account (i.e., conservatively assume a longer half life). Does the SmPC contain data on the variability (±SD)?
❝ The sample size for parallel design (I think Helmut mentioned this to me before, right Helmut? ) is based on the total CV (intersubject CV and intrasubject CV).
Yessir.
❝ 90% CI computation will be done using the intersubject CV
Nope. The residual variance in a parallel design is also the total. What Niazi writes:
The width of the confidence interval is determined by the within-subject variance (between-subject variance for parallel group studies) and the number of subjects in the study.
is wrong (or another example of sloppy terminology). In a parallel design between-subject variance is not accessible – only total (or pooled if you prefer).@Ken:
❝ The comparator product […] reported in their product insert an elimination half-life of 18 days. To fulfill the washout period of 5 half-life, the washout period will be about 90 days.
Don’t fall into the trap of basing you design on a reported mean value. Take the variability into account (i.e., conservatively assume a longer half life). Does the SmPC contain data on the variability (±SD)?
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- drugs of long half life Ken Peh 2013-03-31 06:43 [Design Issues]
- drugs of long half life jag009 2013-04-02 15:17
- drugs of long half lifeHelmut 2013-04-02 15:34
- drugs of long half life jag009 2013-04-02 16:01
- drugs of long half life Helmut 2013-04-02 16:40
- parallel FDA d_labes 2013-04-04 08:33
- parallel FDA jag009 2013-04-05 18:01
- parallel FDA jag009 2013-04-05 21:10
- random repeated parallel FDA d_labes 2013-04-08 08:29
- Proc Mixed: random repeated parallel FDA jag009 2013-04-08 15:36
- Proc Mixed: parallel groups with different variabilities d_labes 2013-04-08 16:41
- Proc Mixed: parallel groups with different variabilities jag009 2013-04-08 20:22
- Proc Mixed: parallel groups with different variabilities d_labes 2013-04-08 16:41
- Proc Mixed: random repeated parallel FDA jag009 2013-04-08 15:36
- random repeated parallel FDA d_labes 2013-04-08 08:29
- parallel FDA d_labes 2013-04-04 08:33
- drugs of long half life Helmut 2013-04-02 16:40
- drugs of long half life jag009 2013-04-02 16:01
- drugs of long half life Ken Peh 2013-04-04 15:03
- drugs of long half life jag009 2013-04-05 17:45
- drugs of long half lifeHelmut 2013-04-02 15:34
- drugs of long half life jag009 2013-04-02 15:17